Kriangkrai Tawinprai

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines

Guy Cohen, Pawornrath Jungsomsri, Jirath Sangwongwanich et al. · Human Vaccines & Immunotherapeutics · 2022 · 19 citations · Full text

Vaccination, Vaccine Safety, Preventive Medicine +15

Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)

Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Kriangkrai Tawinprai et al. · International Journal of Infectious Diseases · 2023 · 17 citations · Full text

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial

Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon et al. · Vaccine · 2022 · 16 citations · Full text

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Kriangkrai Tawinprai et al. · Phytomedicine · 2023 · 16 citations · Full text

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand

Saraiorn Thonginnetra, Kriangkrai Tawinprai, Krongkwan Niemsorn et al. · Vaccines · 2022 · 15 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +14